Evidence mapPaperPMID 39441380Full record

ArticleCellular and molecular neurobiology2024

Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal Neurodegeneration.

Mahdieh Taheri, Mehrdad Roghani, Reza Sedaghat

Abstract read
In one paragraph

Article in Cellular and molecular neurobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mahdieh TaheriDepartment of Biology, Faculty of Basic Sciences, Shahed University, Tehran, Iran.ORCID http://orcid.org/0000-0002-7898-9969
Mehrdad RoghaniNeurophysiology Research Center, Shahed University, Tehran, Iran. mroghani@shahed.ac.ir.ORCID http://orcid.org/0000-0002-9209-8484
Reza SedaghatDepartment of Pathology, School of Medicine, Shahed University, Tehran, Iran.ORCID http://orcid.org/0000-0003-0023-7131

Funding

Shahed University 503285
6 · The paper itself

Abstract

The neurotoxicant trimethyltin (TMT) triggers cognitive impairment and hippocampal neurodegeneration. TMT is a useful research tool for the study of Alzheimer's disease (AD) pathogenesis and treatment. Although the antidiabetic agent metformin has shown promising neuroprotective effects, however, its precise modes of action in neurodegenerative disorders need to be further elucidated. In this study, we investigated whether metformin can mitigate TMT cognition impairment and hippocampal neurodegeneration. To induce an AD-like phenotype, TMT was injected i.p. (8 mg/kg) and metformin was administered daily p.o. for 3 weeks at 200 mg/kg. Our results showed that metformin administration to the TMT group mitigated learning and memory impairment in Barnes maze, novel object recognition (NOR) task, and Y maze, attenuated hippocampal oxidative, inflammatory, and cell death/pyroptotic factors, and also reversed neurodegeneration-related proteins such as presenilin 1 and p-Tau. Hippocampal level of AMP-activated protein kinase (AMPK) as a key regulator of energy homeostasis was also improved following metformin treatment. Additionally, metformin reduced hippocampal acetylcholinesterase (AChE) activity, glial fibrillary acidic protein (GFAP)-positive reactivity, and prevented the loss of CA1 pyramidal neurons. This study showed that metformin mitigated TMT-induced neurodegeneration and this may pave the way to develop new therapeutics to combat against cognitive deficits under neurotoxic conditions.

Indexed as

Cognitive DysfunctionHippocampusMetforminTrimethyltin CompoundsAnimalsMaleMaze LearningNerve DegenerationNeurodegenerative DiseasesNeuroprotective AgentsOxidative StressMetforminNeuroprotective AgentstrimethyltinTrimethyltin CompoundsAlzheimer’sAMP-activated protein kinaseMetforminNeurodegenerationNeuroprotectionTrimethyltin

Identifiers

PMID39441380
PMCPMC11499442

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.